BioCryst Pharmaceuticals, Inc. announced the company has entered into a collaboration with Swixx BioPharma AG to commercialize ORLADEYO(R) (berotralstat) in Central and Eastern Europe (CEE). Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -0.37% | +19.55% | -11.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.19% | 1.1B | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Selects Swixx BioPharma as Commercial Partner for ORLADEYO(R) (berotralstat) in Central and Eastern Europe